Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of BBV121 Zika Vaccine
NCT04478656Phase 1Completed
- Sponsor
- Bharat Biotech
- Start
- Jun 2017
- Primary completion
- Nov 2017
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BBV121 in Zika virus infection (4 arms), sponsored by Bharat Biotech. Primary endpoint: Occurrence of adverse events and Serious Adverse events at 12 months. Started Jun 2017; status: completed.
02
Drugs
BBV121
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT04478656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04478656.